Spread the love

A study from the Gene Expression Laboratory, Salk Institute, La Jolla, California 92037, USA shows that Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy.”

This study was published in the 25 September issue of 2014 Cell (The no. 1 journal in Biological Sciences with an I.F of 35.025) by Prof. Ronald M. Evans, Mara H. Sherman, Prof. Tony Hunter, Prof. Geoffrey M. Wahl and others from the Salk Institute, La Jolla, California 92037, USA

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Therapeutic insights into the treatment of Pancreatic Cancer: Tumor suppressor p53 homolouge p73 and p63 inhibit the conversion of quiescent to activated pancreatic stellate cells and suppress Pancreatitis via up regulation of their target genes.  This study may suggest that p73 and p63, by up regulating their target genes, they may reprise the quiescent state. Thereby, they may (1) decrease tumor volume; (2); enhance survival; and (3) overcome chemotherapeutic drug resistance. Together, this study suggests that pharmacological formulations encompassing “p73 and p63 activators can be used to inhibit the progression of Pancreatic cancer.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, L., Therapeutic insights into the treatment of Pancreatic Cancer: Tumor suppressor p53 homolouge p73 and p63 inhibit the conversion of quiescent to activated pancreatic stellate cells and suppress Pancreatitis via up regulation of their target genes, 9/October/2014, 16.02, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation


Spread the love